MD; for the TIMI II Investigators Background. Percutaneous transluminal coronary angioplasty (PTCA) of the infarct-related artery was performed within 42 days of recombinant tissue-type plasminogen activator (rt-PA) administration in 1,414 of the 3,534 patients who participated in the Thrombolysis In Myocardial Infarction (TIMI) II study. Primary angiographic success was obtained in 88.7%, with bypass surgery within 24 hours in 3.3% and death within 24 hours in 0.7% of patients. By 1 year, 25.1% of the 1,414 patients had sustained one or more adverse outcomes including death (3.6%), reinfarction (8.4%), or the need for further revascularization (20%o).
rent myocardial infarction, or improved left ventricular function at hospital discharge compared with a conservative management strategy in which catheterization and PTCA were reserved for recurrent spontaneous or exercise-induced ischemia.1"2 Distinct from issues regarding these management strategies, however, are questions relating to baseline anatomic findings, procedural success, PTCA-related complications, and the incidence of recurrent ischemia resulting from restenosis among patients who underwent PTCA procedures within the TIMI II study. As such, this report looks more closely at the 1,414 PTCA procedures themselves.
Methods
Details of the TIMI protocol have been described previously.' In brief, patients under age 76 years presenting within 4 hours of symptom onset with evidence of evolving transmural myocardial infarction and no contraindication to thrombolytic therapy received intravenous rt-PA (150 mg in the initial 582 patients, 100 mg in the subsequent 2,952 patients). All patients then received intravenous heparin for 5 days and aspirin (80 mg/day on days 2-5, which was increased to 325 mg after conversion from intravenous to subcutaneous heparin administration).
In the IIA substudy (which involved 586 patients treated at seven participating centers whose investigators demonstrated an ability to perform acute PTCA), patients were randomly assigned to one of three treatment strategies: 1) immediate (within 2 hours) catheterization and PTCA if feasible, 2) delayed catheterization (and PTCA if feasible) between 18 and 48 hours after rt-PA, and 3) conservative management in which catheterization and PTCA were reserved for patients with recurrent spontaneous or exercise-induced myocardial ischemia. 2 Contraindications to PTCA attempts included a residual lesion less than 60% in the infarct artery, left main stenosis greater than 70%, situations in which abrupt closure would likely cause hemodynamic collapse, and (at operator discretion) lesion morphology poorly suited to PTCA (excessive length, tortuosity, or involvement of a major bifurcation). Except for patients in the immediate invasive arm, protocol design discouraged PTCA of totally occluded infarct arteries not prompted by recurrent ischemia. All patients in the IIA study were encouraged to undergo predischarge cardiac catheterization, left ventriculography, and coronary cineangiography even if PTCA was not initially performed.
In the larger IIB study, 2,948 patients treated at the participating centers (including the IIA sites after completion of that substudy) received similar initial treatment. These patients were randomly assigned to either the delayed invasive or the conservative strategies as described above. A second randomization (to immediate versus delayed initiation of /3-blocker therapy) was performed in patients without contraindications. Unlike the IIA substudy, a catheterization procedure was not performed in conservatively managed patients unless they had evidence of recurrent ischemia.
Because PTCA results may depend on operator experience, all PTCA operators had to be precertified by the PTCA subcommittee before being allowed to perform TIMI PTCA. Minimal requirements at trial initiation (circa 1985) were experience with more than 100 PTCA procedures (more than 200 procedures for operators in the IIA substudy) with a success rate greater than 85%, emergency surgery rate less than 5%, and mortality rate less than 1%. Sample dilatation cineangiograms performed by each prospective operator were also reviewed by the PTCA committee members before certification.
Baseline angiography of noninfarct-related and infarct-related vessels was performed in a series of specified orthogonal projections. Heparin (5, 000 units) was given intravenously and supplemented by an additional 5,000 units if PTCA were to be attempted. Coronary angioplasty was performed using predominantly over-the-wire systems. The infarct artery was determined from the entry electrocardiogram, ventriculographic contraction abnormality, and coronary angiographic findings. A 0.014, 0.016, or 0.018-in. guide wire was then advanced across the target lesion, over which an appropriate size balloon dilatation catheter was advanced. Dilatation of other than the infarct artery was discouraged. After removal of the PTCA guide wire, the post-PTCA result was documented in at least two of the views used for baseline angiography.
Intravascular sheaths were generally removed on the day after angioplasty. For 2 hours before sheath removal, the heparin infusion (usually 1,000 units/hr but adjusted upward or downward to maintain an activated partial thromboplastin time 1.5 to two times control) was halved and was then returned to its previous infusion rate 2 hours later until a full 5 days of intravenous heparin infusion was completed after rt-PA administration. By protocol, coronary angiography was performed at the time of hospital discharge in 472 of the 586 patients participating in the IIA substudy.
The quality of the angiographic procedures and the compliance of the certified TIMI PTCA operators with the protocol were assessed by the angiographic core laboratory. On-site angiographic interpretations were confirmed by that laboratory, which also performed quantitative lesion and contrast ventriculographic measurements. All angiographic data included in this report were derived from core laboratory analysis. Predischarge radionuclide ventriculograms were analyzed by the radionuclide core laboratory. Adverse outcomes were reviewed and confirmed by a mortality and morbidity committee. All core laboratory measurements and clinical data were incorporated into a central data bank maintained at the TIMI coordinating center (Maryland Medical Research Institute).
This report is based on all data processed by the TIMI coordinating center as of September 1990. All analyses were performed using either the SAS3 or BMDP4 programs. To adjust for the effects of multiple testing, probability values between 0.01 and 0.001 were judged as providing some evidence of group differences, and values less than 0.001 were judged as providing strong evidence of group differences not due to chance alone. Stepwise logistic regression and Cox regression were used to identify independent variables associated with specific outcome measures.
Results

Characteristics of PTCA Patients
The 1,414 patients were 56.1+0.3 (mean+SEM) years old and were predominantly (82.5%) men (Table 1) . Infarctions were nearly equally divided between anterior and inferior location and overwhelmingly represented each patient's first infarction; only 11.8% of patients reported a prior myocardial infarction. The time from pain onset to rt-PA 11.8 24.9 All figures are given as a percent of total number of patients in the respective column, except as indicated. Assigned PTCA refers to percutaneous transluminal angioplasty (PTCA) procedures performed in patients randomly placed in the immediate invasive or delayed invasive strategies; Nonassigned (ischemia-driven) PTCA refers to PTCA procedures performed in patients randomly placed in the conservative strategy.
Success denotes angiographic success. MI, myocardial infarction; BP, blood pressure; IRA, infarct-related artery; LAD, left anterior descending; RCA, right coronary artery; CX, circumflex; Flow 0-1, TIMI grade flow; LVEF, left ventricular ejection fraction by hospital discharge (Hosp dis) radionuclide ventriculography (RVG) (n =number of patients with RVG performed; patients not represented in a specified range of ejection fraction are those in whom discharge radionuclide ventricular ejection fraction was not available); CABG, coronary artery bypass graft. treatment was 2.6 hours: 27.2% of patients had treatment initiated within 2 hours of pain onset, and 1,251 patients (88.5%) had ongoing chest pain at the time of rt-PA initiation.
Cardiogenic shock was not a criterion for exclusion from TIMI, but only 14 patients (1%) were in cardiogenic shock at the time of study entry. There was no routine evaluation of ventricular function at the time of study entry, but mean radionuclide left ventricular ejection fraction at the time of hospital discharge (available in 1,159; 82% of the 1,414 patients) was 51.7±0.4%. Discharge ejection fraction was greater than 55% in 468 patients (33.1%), between 35% and 55% in 576 patients (40.7%), and less than 35% in 115 patients (8.1% ). In the remaining 255 patients (18%), discharge radionuclide angiography was not available due to clinical limitations or in-hospital death.
The infarct-related vessel was most commonly the left anterior descending coronary artery (LAD) (612 patients, 43.3%) or the right coronary artery (RCA) (638 patients, 45.2%) rather than the circumflex coronary artery (162 patients, 11.5%). Multivessel disease (defined as greater than 60% stenosis in two or more major branches of the coronary arteries) was present in 402 patients (30.4%) and included two-vessel disease in 334 and three-vessel disease in 68 patients. At the time of PTCA, 148 patients (10.5%) had total occlusion of the infarct-related vessel before attempted angioplasty (5.7% TIMI grade 0 and 4.8% TIMI grade 1 flow). The remainder were patent, with TIMI grade 2 (25.8%) or grade 3 (63.7%) flow. Stenosis in the infarct artery before PTCA averaged 80.5 ± 0.3% by core laboratory determination.
Results of PTCA
The overall results of PTCA were favorable, with 80.5% full angiographic success (defined as normal or improved TIMI flow grade with both improvement of the stenosis by greater than 20% and a residual stenosis less than 60%) and 8.2% partial angiographic success (defined as unchanged or improved flow grade with either a residual stenosis less than 60% or improvement in stenosis greater than 20%). The mean post-PTCA stenosis was 34.2±0.6%, with stenosis 0-20% in 499 (35.6%), 21-40% in 612 (43.6%), and 41-60% in 154 (11.0%). Post-PTCA flow was predominantly grade 2 (134 patients, 9.6%) or 3 (1,204 patients, 85.9%) but was markedly impaired in a small number of patients (grade 0, 43 patients, 3.1%; grade 1, 20 patients, 1.4%). PTCA was angiographically unsuccessful in 11.3% of patients. The most commonly cited specific reasons for lack of angiographic success were failure to cross the lesion in 27 patients (1.9%), inability to dilate the lesion in 23 patients (1.6%), and sustained reocclusion in 27 patients (1.9%).
Major adverse outcomes within 24 hours of the PTCA procedure included the need for bypass surgery (46 patients, 3.3%), repeat PTCA (20 patients, 1.4%), reinfarction (56 patients, 4.0%), or death (10 patients, 0.7%). By 30 days after PTCA, a cumulative total of 190 patients (13.4%) had sustained one or more adverse outcomes including bypass surgery (87 patients, 6.2%), repeat PTCA (53 patients, 3.8%), reinfarction (85 patients, 6.0%), or death (35 patients, 2.5%).
New adverse events were relatively uncommon (11.7%) beyond 30 days after PTCA. Of 50 patients who died within the first year, only 15 did so during the interval after 30 days. Similarly, of the 146 patients who had at least one repeat PTCA, only 93 were treated between 30 days and 1 year. Of 155 patients who underwent subsequent bypass surgery, only 68 did so between 30 days and 1 year after the index PTCA.
The TIMI protocol did not require routine late (6 months to 1 year) angiography as would be necessary to evaluate the true incidence of restenosis. An estimation of restenosis, however, can be obtained from analysis of repeat revascularization procedures performed between 24 hours and 1 year after the index angioplasty procedure. Revascularization procedure performed before 24 hours can be taken to reflect thrombotic occlusion of the infarct-related artery or treatment of other vessels rather than traditional restenosis. Of 217 repeat revascularization procedures between 24 hours and 1 year, 165 procedures involved retreatment of the infarct artery (consistent with an 11.7% incidence of documented restenosis). The remaining 52 repeat revascularization procedures performed between 24 hours and 1
year involved treatment of either new, progressive, or persistent disease in other vessels.
Analysis of symptom-driven late revascularization procedures, however, clearly underestimates the true incidence of restenosis. This is particularly true in a population whose symptoms may be blunted due to either well-developed collaterals or completed regional infarction. We therefore also looked at the occurrence of death, myocardial infarction, PTCA, or coronary artery bypass graft (CABG) among patients who were alive and CABG free at 24 hours after the index PTCA procedure. Although this approach may underestimate or overestimate the true incidence of restenosis, it showed that 276 (20.3%) of 1,361 patients at risk (alive and CABG free at 24 hours) exhibited one or more of these end points between 24 hours and 1 year after the index PTCA. There were no significant differences in these late events among the clinically and anatomically defined subgroups described below.
Effect of Indication and Timing on PTCA Outcome
In TIMI II, a PTCA procedure could be performed under one of two circumstances: 1) 1,048 patients had assigned PTCA (performed either immediately [141 patients] or at 18-48 hours after rt-PA administration [907 patients]) as specified by protocol assignment even in the absence of recurrent ischemia, and 2) 366 patients had nonassigned (ischemiadriven) PTCA. The latter patients can be divided between PTCA procedures performed within 15 hours of enrollment (86 patients), between 15 and 48 hours (37 patients), and between 2 and 42 days (243 patients).
Comparison of assigned immediate to assigned delayed (18-48 hours) PTCA (Table 1) showed that the former were performed on more severe stenoses (p<0.001). Moreover, these immediate PTCA procedures were less likely than their delayed assigned PTCA counterparts to be angiographically successful (p<0.001), left a greater residual stenosis (p<0.001), and had a greater incidence of TIMI 0-1 flow (p=0.04) after the PTCA attempt. Assigned immediate procedures also carried a higher incidence of adverse outcomes by 30 days, including CABG, re-PTCA, and death (5.0% versus 1.8%, p=0.015).
Among the patients who were randomized to the conservative strategy, 366 underwent nonassigned PTCA because of recurrent ischemia. The 86 (23.8%) who underwent PTCA within 15 hours of study entry (Table 1) were young (p=0.001), male (p=0.003), and tended to have cardiogenic shock from a first infarction. Although they tended to have mostly one-vessel disease (p=0.05), that vessel was more severely diseased (p=0.002) and more likely to be occluded (p=0.001) before PTCA than were the infarct-related vessels in other nonassigned PTCA patients. Despite an 84.9% incidence of angiographic PTCA success (complete or partial), the incidence of an occluded vessel after attempted PTCA was higher (p=0.007). Although mean discharge left ventricular ejection fraction (LVEF) was 48.5±+ 1.5%, 16.3% had an ejection fraction (EF) below 35%. The incidence of death by 30 days was also significantly (p=0.006) higher than other nonassigned PTCA patients. There were few further complications between 30 days and 1-year follow-up, but the subgroup having nonassigned PTCA within 15 hours of rt-PA administration had a 9.3% mortality rate at 1 year. These findings compared most closely with the assigned immediate PTCA subset but were remarkable for an even higher incidence of baseline (p<0.001) and post-PTCA (p=0.06) occlusion despite significantly (p=0.011) lower mean post-PTCA stenosis.
The 37 patients having nonassigned PTCA between 15 and 48 hours had characteristics and results intermediate between the less-than-15-hour and the 2-42-day nonassigned PTCA groups. Patients having nonassigned PTCA between 2 and 42 days (243 patients) had similar baseline clinical characteristics and 1-year outcomes to those undergoing assigned delayed PTCA (n=907).
In the 280 patients in the conservative arm who had nonassigned PTCA more than 15 hours after initiation of rt-PA, the precipitant was suspected reinfarction in 32 patients, angina or clinical deterioration in 134 patients, a positive exercise test in 46 patients, and other (predominantly patient or physician preference) in 68 patients (Figure 1 and Table   2 ). Not unexpectedly, the group treated for suspected reinfarction had more pre-PTCA occlusion (p<0.01) and higher (p=0.008) mean baseline stenosis. Angioplasty was deemed unsuccessful predominantly because of inability to dilate or sustained reocclusion of the target lesion; post-PTCA stenosis was more severe (p=0.03), and there was a tendency toward a higher incidence of TIMI 0-1 flow after PTCA than was present in other subgroups. Despite a well-preserved mean LVEF at hospital discharge, this group with Effect of Coronary Anatomy Among the 1,414 patients, the results within the first 24 hours did not vary significantly with the identity of the infarct-related artery ( Table 3) . Patients with LAD disease, however, had a significantly (p<O.OOl) lower LVEF at hospital discharge and a greater incidence of EF lower than 35%. This was paralleled by a tendency toward higher mortality at 30 days and 1 year and a slightly greater use of repeat PTCA or CABG.
The infarct-related artery was occluded at the time of attempted PTCA in 148 patients (10.5%), including 76 patients with occlusion of the RCA and 61 patients with occlusion of the LAD. Patients undergoing PTCA of occluded infarct-related arteries were less likely (p=0.014) than patients with stenotic vessels to have multivessel coronary disease and had a tendency (p=0.04) toward less full or partial angiographic PTCA success. They also had a more severe post-PTCA stenosis (p<0.001) with a higher incidence (p<0.001) of TIMI 0-1 flow after PTCA (Table 3) . Overall LVEF at hospital discharge was similar, but mortality was higher (p<0.001) at all time points. Success denotes angiographic success. MI, myocardial infarction; BP, blood pressure; IRA, infarct-related artery; LAD, left anterior descending; RCA, right coronary artery; CX, circumflex; Flow 0-1, TIMI grade flow; LVEF, left ventricular ejection fraction by hospital discharge (Hosp dis) radionuclide ventriculography (RVG) (n=number of patients with RVG performed; patients not represented in a specified range of ejection fraction are those in whom discharge right ventricular ejection fraction was not available); CABG, coronary artery bypass graft.
Multivessel disease (defined as stenosis greater than 60% in a vessel other than the infarct-related artery) was present in 402 (30.4%) of the 1,414 patients but included two-vessel disease in 334 patients and three-vessel disease in 68 patients (Table 3) . Patients with multivessel disease were more likely (p=0.001) to have a history of angina or infarction and were less likely (p=0.005) to have anterior infarction but oth- Success denotes angiographic success. MI, myocardial infarction; BP, blood pressure; IRA, infarct-related artery; LAD, left anterior descending; RCA, right coronary artery; CX, circumflex; Flow 0-1, TIMI grade flow; LVEF, left ventricular ejection fraction by hospital discharge (Hosp dis) radionuclide ventriculography (RVG) (n=number of patients with RVG performed; patients not represented in a specified range of ejection fraction are those in whom discharge radionuclide ventricular ejection fraction was not available); CABG, coronary artery bypass graft. erwise had similar baseline characteristics, acute results, and radionuclide EF at hospital discharge to patients with one-vessel disease. Patients with multivessel disease (and in particular, three-vessel disease) had a significantly greater incidence of late revascularization (PTCA or CABG, 29.2% for two-vessel and 47.1% for three-vessel disease compared with 14.6% for patients with one-vessel disease, p<O.OO1) ( Figure   59 2). Their 1-year mortality of 5.8% (4.8% for two-vessel and 10.3% for three-vessel disease) was also significantly (p=0.007) higher than the 2.7% 1-year mortality rate of patients with one-vessel disease.
Multivariate Predictors ofAdverse Outcome Although the results of PTCA in this study were generally favorable, adverse outcomes included 1) unsuccessful PTCA, 2) CABG or repeat PTCA within 1 year of initial treatment, and 3) death or recurrent myocardial infarction within 1 year of treatment. To characterize which patients were most likely to have these adverse outcomes, stepwise logis-tic regression or stepwise Cox regression was performed using 24 covariates including baseline clinical and anatomic variables, indication and timing of PTCA, and treatment in a TIMI IIA versus IIB clinical center (Table 4 ). It should be noted that EF was not included in this analysis because of the incomplete (82%) ascertainment of this variable, particularly in patients with a complicated hospital course.
Unsuccessful PTCA correlated most highly with the performance of assigned immediate PTCA (RR, 2.7; p< 0.001) and age greater than 70 years (RR, 1.7; p=0.03). A similar trend (RR, 1.8; p=0.1) was seen for nonassigned PTCA within the first 15 hours and for multivessel disease (RR, 1.4; p=0.08).
CABG or repeat PTCA within 1 year correlated most highly with the presence of multivessel disease (RR, 2.5; p<0.001) and history of angina (RR, 1.4; p=0.006). Repeat revascularization by 1 year also tended to be more common with PTCA of the LAD (RR, 1.3;p<0.05) and nonassigned immediate PTCA (RR, 1.7; p=0.02).
Death or recurrent myocardial infarction within 1 year correlated strongly with the presence of multivessel disease (RR, 1.6; p=0.007) and history of angina (RR, 1.5; p=0.014). Discussion Percutaneous transluminal coronary angioplasty, with or without antecedent thrombolytic therapy, remains the technique of choice for the mechanical revascularization of most patients with acute myocardial infarction. Prior studies have demonstrated a high (90-95%) degree of successful dilatation, a relatively low (2-5%) incidence of emergency bypass surgery, and a moderate (10-15%) need for repeat revascularization within the year after treatment. [5] [6] [7] [8] Overall Results
The TIMI II trial, which includes more than 1,400 myocardial infarction patients treated with PTCA, represents the largest such series reported to date. Its overall results, showing a primary success rate of 88.7%, an emergency revascularization rate within 24 hours of 4.5% (CABG in 3.3% and repeat PTCA in 1.4%), and a mortality rate within 24 hours of 0.7%, are in basic agreement with prior studies. These favorable early results were generally well maintained over the next year despite a cumulative mortality rate of 3.6%, a reinfarction rate of 8.4%, and a cumulative subsequent revascularization rate of 20.0% (repeat PTCA in 10.6% and CABG in 11.2%) . What unique observations can be made from this large series of patients who underwent coronary angioplasty in the setting of acute myocardial infarction?
Results for Various Clinical and Anatomic Subgroups
Because of the size and diversity of the TIMI PTCA population, it is possible to examine PTCA results in subsets of patients with different clinical characteristics, indications for, and timing of PTCA A intervention. This examination discloses several subsets of patients for whom early and late results are far less favorable. One such group, patients undergoing assigned immediate PTCA after rt-PA administration, has already been reported to have a lower acute success rate, a higher complication rate, and a greater early and 1-year mortality rate. 2 The lower immediate success rate in this group is strongly confirmed by multivariate analysis.
Not surprisingly, the current study also identifies the comparatively small group (n=86) of patients undergoing urgent (less than 15 hours) PTCA for management of recurrent ischemia after rt-PA administration as having a high risk of unfavorable outcome. Such patients were less likely to have an angiographically successful PTCA, more likely to have a persistently occluded infarct-related vessel after the PTCA attempt, and had an 8.1% mortality rate by 30 days. This poor outcome may be related in part to worse left ventricular function, because 16.3% had an EF below 35% at hospital discharge.
Patients undergoing nonassigned PTCA between 15 and 48 hours for treatment of recurrent ischemia had somewhat more satisfactory results, and those undergoing nonassigned PTCA for ischemia after 48 hours had results approximating those of the most favorable (assigned delayed) angioplasty cohort. One exception was the group of 32 patients who underwent nonassigned PTCA after 15 hours for the treatment of suspected myocardial infarction: They had a lower angiographic success rate and a 9.4%
1-year mortality despite a well-preserved mean discharge EF of 55.8+2.4%. In addition to the variation in PTCA results with procedure timing and indications, short-term and long-term outcome also varied with underlying coronary anatomy.9"10 Despite a comparable PTCA success rate, patients with the LAD as their infarctrelated artery had lower mean LVEF at discharge, a somewhat higher mortality rate at 1 year, and a slightly greater use of late revascularization. We were not, however, able to confirm prior suggestions of adverse outcome with PTCA of the RCA in the setting of inferior wall myocardial infarction.9"10 Regardless of the identity of the infarct-related artery, patients undergoing PTCA of an occluded vessel were less likely to have an angiographically successful procedure, were four times more likely to have an occluded vessel (TIMI 0-1 grade flow) after PTCA, and were three times more likely to have died by 1 year. These findings have been noted previously9 but did not correlate with adverse outcomes under multivariate evaluation in the present study suggesting that the apparently poor results in patients with occluded arteries may have been confounded by the inclusion of patients undergoing PTCA soon after rt-PA and those undergoing PTCA in the setting of suspected reinfarction.
Even though PTCA was generally limited to the infarct vessel alone, by far the most potent predictor of unfavorable PTCA outcome was the presence of multivessel disease. Multivessel disease was present in a minority (30.4%) of the TIMI PTCA population, including 334 patients with two-vessel and 68 patients with three-vessel disease. Despite similar results within the first 24 hours and discharge LVEF, patients with multivessel coronary artery disease had more than twice the mortality of one-vessel disease patients, and more than three times the incidence of bypass surgery by 1 year. As such, the presence of multivessel coronary artery disease was the strongest multivariate correlate of adverse late outcome. This finding has been evident in other series of acute myocardial infarction angioplasty11,12 and is not unexpected, given the less favorable general outlook for angioplasty patients with multivessel coronary artery disease. 13 Other General Observations It has been widely recognized that PTCA performed for the management of acute myocardial infarction has less favorable success and higher complication rates than PTCA performed for the management of stable or unstable angina. The current report extends this observation to several clinical and anatomic subgroups of acute myocardial infarction patients who have even less favorable outcomes but does not identify the pathophysiological mechanisms that underlie these unfavorable outcomes.
To some extent, patients with myocardial infarction are to be expected to have higher early and late mortality rates than elective PTCA patients, based on impaired ventricular function and arrhythmic instability. Lower immediate angiographic success, however, points to fundamental differences in the coronary lesion present in the patient with acute infarction. Specifically, these lesions are more likely to have associated thrombus, particularly if PTCA is attempted within the first 48 hours, for treatment of total occlusion, or in the setting of suspected recurrent infarction. Perhaps the presence of thrombus, combined with a general prothrombotic state that persists despite the administration of rt-PA and heparin, serves to lower the likelihood of immediate success and increase the incidence of vessel reocclusion after dilatation.9 This inherent prothrombotic tendency may have been further unmasked in our patients undergoing angioplasty within the first 24 hours after rt-PA because the TIMI protocol did not initiate aspirin therapy until the following day. If the problem of thrombosis were exacerbated by the more complex plaque morphology that appears to underlie acute infarction,14 it might explain the observed failure modes of PTCA and worse quantitative angiographic results among patients treated soon after rt-PA, those treated for reinfarction, and those undergoing PTCA of occluded arteries.
More intriguing is the low (20.0%) cumulative incidence of repeat revascularization in the overall TIMI PTCA population compared with elective PTCA patients.14 Of the 921 patients with one-vessel disease who underwent PTCA, 132 (14.6%) required repeat revascularization within 1 year of initial treatment, of which 33 (3.6%) were performed within 24 hours, reflecting thrombotic occlusion rather than conventional restenosis, and 2.8% were performed for treatment of progressive disease in another segment.
Among the 402 patients with multivessel disease, 126 (32.2%) underwent repeat PTCA or CABG within the subsequent year, of which 24 (6%) were performed within 24 hours and 6.7% were performed for treatment of additional or progressive disease at other sites. These low (10-20%) rates of apparent restenosis may simply reflect a lack of recurrent symptoms in patients with extensive infarction in the territory of the restenotic vessel15 rather than a truly lower incidence of anatomic restenosis in acute infarction compared with elective PTCA patients.16 A lower restenosis rate might seem reasonable based on less severe underlying atherosclerotic stenosis, but without routine late angiographic follow-up, incomplete ascertainment cannot be excluded as the operative mechanism.
Conclusions
The TIMI II study contains detailed data on more than 1,400 patients who underwent PTCA of an infarct-related artery within 6 weeks after rt-PA treatment for acute myocardial infarction; it confirms the overall favorable short-term and long-term results of PTCA in this application and delineates clinical (early PTCA, particularly when driven by recurrent ischemia, suspected reinfarction) and anatomic (multivessel disease, PTCA of occluded vessels) factors associated with less promising results. Although PTCA remains the treatment of choice in patients with recurrent ischemia after rt-PA thrombolysis for acute myocardial infarction, additional analysis should be performed to determine whether some high-risk subgroups (e.g., those with multivessel disease) might be better served by bypass surgery, given their generally poor 1-year results with PTCA in this setting. The other subsets in which less favorable PTCA results were observed suggest that it may be, in part, the presence of thrombus or a prothrombotic state that underlies these less satisfactory results. Although our observations cannot necessarily be extended to patients undergoing primary PTCA or PTCA after other thrombolytic regimens,'7 they do offer a yardstick against which the results of PTCA after myocardial infarction can be evaluated.
